CSL Behring gene therapy makes comeback after hold for FDA priority reviewnews2022-05-24T14:29:16+00:00May 24th, 2022|FierceBiotech|
Genocea closes up shop after failing to find a buyer, delists from Nasdaqnews2022-05-24T14:18:23+00:00May 24th, 2022|FierceBiotech|
Manufacturing concerns sideline INmune’s US Alzheimer’s trialnews2022-05-24T13:46:53+00:00May 24th, 2022|FierceBiotech|
Supply chain challenges upend Caladrius’ coronary artery disease trialnews2022-05-24T13:24:47+00:00May 24th, 2022|FierceBiotech|
When will biotech markets get better? BridgeBio fears they may stay ‘pretty bad’ until 2024news2022-05-24T12:39:00+00:00May 24th, 2022|FierceBiotech|
Boing! SpringWorks’ stock jumps as phase 3 tumor trial hits goalnews2022-05-24T11:23:22+00:00May 24th, 2022|FierceBiotech|
Moderna tunes vaccine platform to next potential viral threat: monkeypoxnews2022-05-23T20:33:48+00:00May 23rd, 2022|FierceBiotech|
After COVID and new global disruptions, Eli Lilly does victory lap with UC datanews2022-05-23T18:27:23+00:00May 23rd, 2022|FierceBiotech|
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin out preps FDA filingnews2022-05-23T14:54:16+00:00May 23rd, 2022|FierceBiotech|
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spinout preps FDA filingnews2022-05-23T14:54:16+00:00May 23rd, 2022|FierceBiotech|
